Trials / Completed
CompletedNCT02841865
Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 104 (actual)
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The Response Evaluation Criteria in Solid Tumors (RECIST), based on differences in tumor size, has been considered as a reproducible method that facilitates not only the measurement of the mass but the evaluation of response to given treatments; while classic chemotherapy induces a reduction of the tumor, new target therapies frequently produce the stabilization of the disease or a delayed progression. These new therapeutic alternatives have shade light on the limitations of the RECIST criteria, since the response to these type of treatments are basically associated with changes on the radiological characteristics of the tumor, as well as other findings in functional imaging. This study is aimed to compare the response rates according both Choi and RECIST criteria.
Conditions
Timeline
- Start date
- 2015-07-24
- Primary completion
- 2017-12-01
- Completion
- 2018-04-01
- First posted
- 2016-07-22
- Last updated
- 2020-03-24
Locations
10 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02841865. Inclusion in this directory is not an endorsement.